Drug intelligence / Profile preview

p55-PEG

Development stage: Preclinical
Lead developer: Amgen
Modality: PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes

Overview

p55-PEG is a pegylated, soluble form of the human p55 tumor necrosis factor receptor. It functions as an anti-TNFalpha agent, designed to neutralize both transmembrane (tmTNFalpha) and secreted forms of tumor necrosis factor alpha (TNFalpha). This mechanism is being investigated for its potential to treat inflammatory conditions like rheumatoid arthritis.

Other names: soluble human p55 tumor necrosis factor receptor-PEG

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on p55-PEG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on p55-PEG.

Explore the full profile